Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions

Overview

Journal J Atheroscler Thromb

Date 2020 Sep 1

PMID 32863296

Citations 5

Authors

Koji Yanaka

Hirokuni Akahori

Takahiro Imanaka

Kojiro Miki

Nagataka Yoshihara

Toshio Kimura

Takamasa Tanaka

Masanori Asakura

Masaharu Ishihara

Affiliations

Soon will be listed here.

Abstract

Aim: High levels of lipoprotein(a) [Lp(a)] are a risk factor for peripheral artery disease (PAD). However, the relationship between Lp(a) levels and the severity of femoropopliteal lesions in patients with PAD has not been systematically studied. This study aimed to assess the impact of Lp(a) levels on angiographic severity of femoropopliteal lesions in patients with PAD.

Methods: We retrospectively analyzed a single-center database including 108 patients who underwent endovascular therapy for de novo femoropopliteal lesions and measured the Lp(a) levels before therapy between June 2016 and September 2019. Patients were divided into low Lp(a) [Lp(a) ＜30 mg/dL; 77 patients] and high Lp(a) [Lp(a) ≥ 30 mg/dL; 31 patients] groups. Trans-Atlantic Inter-Society Consensus (TASC) II classification, calcification [referring to the peripheral arterial calcium scoring system (PACSS) classification], and lesion length were compared between the groups.

Results: The prevalence of TASC II class D (13% vs 38%, P＜0.01) and severe calcification (PACSS 4) (6% vs 23%, P=0.02) was significantly higher and the lesion length longer (123±88 mm vs 175±102 mm, P＜0.01) in the high Lp(a) group than in the low Lp(a) group. In multivariate analysis, Lp(a) ≥ 30 was an independent predictor for the prevalence of TASC II class D (HR=3.67, 95% CI 1.27-10.6, P=0.02) and PACSS 4 (HR=4.97, 95% CI 1.27-19.4, P=0.02).

Conclusion: The prevalence of TASC II class D and severe calcification of femoropopliteal lesions was higher in patients with high Lp(a) than those with low Lp(a).

Citing Articles

Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study.

Liang Q, Zhang G, Jiang L BMC Nephrol. 2024; 25(1):250.

PMID: 39090533 PMC: 11295529. DOI: 10.1186/s12882-024-03690-z.

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels.

Vinci P, Fiotti N, Panizon E, Tosoni L, Cerrato C, Pellicori F Front Cardiovasc Med. 2024; 10:1272288.

PMID: 38322275 PMC: 10845343. DOI: 10.3389/fcvm.2023.1272288.

Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients.

Yi C, Junyi G, Fengju L, Qing Z, Jie C Clin Cardiol. 2023; 46(5):512-520.

PMID: 36896666 PMC: 10189068. DOI: 10.1002/clc.24003.

Association of Smoking, Diabetes, and Dialysis with the Presence of Popliteal Lesions in Femoropopliteal Artery Disease.

Takahara M, Soga Y, Fujihara M, Iida O, Kawasaki D J Atheroscler Thromb. 2023; 30(10):1327-1335.

PMID: 36596532 PMC: 10564636. DOI: 10.5551/jat.64007.

Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia.

Ying Q, Croyal M, Chan D, Blanchard V, Pang J, Krempf M J Atheroscler Thromb. 2022; 30(3):274-286.

PMID: 35676030 PMC: 9981347. DOI: 10.5551/jat.63587.

References

Gurdasani D, Sjouke B, Tsimikas S, Hovingh G, Luben R, Wainwright N . Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012; 32(12):3058-65. PMC: 4210842. DOI: 10.1161/ATVBAHA.112.255521. View

Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J . Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9. DOI: 10.1056/NEJMoa1500858. View

Okuno S, Iida O, Shiraki T, Fujita M, Masuda M, Okamoto S . Impact of Calcification on Clinical Outcomes After Endovascular Therapy for Superficial Femoral Artery Disease: Assessment Using the Peripheral Artery Calcification Scoring System. J Endovasc Ther. 2016; 23(5):731-7. DOI: 10.1177/1526602816656612. View

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R . Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. J Endovasc Ther. 2019; 26(5):613-620. DOI: 10.1177/1526602819860124. View

Bonaca M, Nault P, Giugliano R, Keech A, Lira Pineda A, Kanevsky E . Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2017; 137(4):338-350. DOI: 10.1161/CIRCULATIONAHA.117.032235. View

Robinson J, Farnier M, Krempf M, Bergeron J, Luc G, Averna M . Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489-99. DOI: 10.1056/NEJMoa1501031. View

Nielsen L, Nordestgaard B, Stender S, Niendorf A, Kjeldsen K . Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995; 15(9):1492-502. DOI: 10.1161/01.atv.15.9.1492. View

Gaubatz J, Heideman C, Gotto Jr A, Morrisett J, Dahlen G . Human plasma lipoprotein [a]. Structural properties. J Biol Chem. 1983; 258(7):4582-9. View

10.

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67. DOI: 10.1016/j.jvs.2006.12.037. View

11.

Rocha-Singh K, Zeller T, Jaff M . Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014; 83(6):E212-20. PMC: 4262070. DOI: 10.1002/ccd.25387. View

12.

Danesh J, Collins R, Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102(10):1082-5. DOI: 10.1161/01.cir.102.10.1082. View

13.

McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 330(6144):132-7. DOI: 10.1038/330132a0. View

14.

Kamioka N, Soga Y, Kuramitsu S, Iida O, Hirano K, Suzuki K . Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP). Catheter Cardiovasc Interv. 2017; 90(5):790-797. DOI: 10.1002/ccd.27192. View

15.

Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C . Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014; 37(4):898-907. DOI: 10.1007/s00270-014-0904-3. View

16.

Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D . Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. JACC Cardiovasc Interv. 2014; 7(7):792-8. DOI: 10.1016/j.jcin.2014.01.168. View

17.

Zhou B, Sun D, Wang C, Wu N, Guo Y, Zhu C . Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart Lung Circ. 2019; 28(7):1009-1017. DOI: 10.1016/j.hlc.2018.05.190. View

18.

Munoz-Torrero J, Rico-Martin S, Alvarez L, Aguilar E, Alcala J, Monreal M . Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis. 2018; 276:10-14. DOI: 10.1016/j.atherosclerosis.2018.07.001. View

19.

Dearing D, Patel K, Compoginis J, Kamel M, Weaver F, Katz S . Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009; 50(3):542-7. DOI: 10.1016/j.jvs.2009.04.019. View

20.

Mbewu A, Durrington P . Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis. 1990; 85(1):1-14. DOI: 10.1016/0021-9150(90)90177-k. View